RecruitingNCT06234306
Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
Studying Rare carcinoma of small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Copenhagen University Hospital at Herlev
- Principal Investigator
- Dan Høgdall, MD PhDDepartment of Oncology, Copenhagen University Hospital - Herlev and Gentofte
- Enrollment
- 500 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2033
Study locations (3)
- Department of Oncology, Aarhus University Hospital, Aarhus N, Denmark
- Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet, Copenhagen Ø, Denmark
- Department of Oncology Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark
Collaborators
Aarhus University Hospital · Rigshospitalet, Denmark · University of Copenhagen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06234306 on ClinicalTrials.govOther trials for Rare carcinoma of small intestine
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07347314Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination TherapyNational Cancer Center, Japan
- RECRUITINGPHASE2NCT06835387Study of NALIRIFOX in Advanced Unresectable Small Bowel TumorsTiago Biachi de Castria